TD Cowen raised the firm’s price target on Neurocrine (NBIX) to $170 from $165 and keeps a Buy rating on the shares. The firm said the company reported $53MM, up 267% quarter-over-quarter in Q2 Crenessity revenue, more than doubling consensus, with 664 start forms.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $141 from $137 at Wedbush
- Buy Rating for Neurocrine’s Crenessity Driven by Strong Sales and Transformative Impact on CAH Treatment
- Neurocrine price target raised to $145 from $140 at JPMorgan
- Neurocrine’s Strong Financial Performance and Growth Prospects Drive Buy Rating
- Neurocrine’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Commercial Execution and Growth Opportunities